Head to Head Contrast: Zealand Pharma A/S (ZLDPF) and Its Competitors

Zealand Pharma A/S (OTCMKTS:ZLDPF) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Zealand Pharma A/S to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zealand Pharma A/S and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	8	1	2	2.45
Zealand Pharma A/S Competitors	9838	15122	45436	1587	2.54

As a group, “Biotechnology” companies have a potential upside of 102.62%. Given Zealand Pharma A/S’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Zealand Pharma A/S has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Zealand Pharma A/S and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	$977.29 million	5.74
Zealand Pharma A/S Competitors	$728.25 million	$12.25 million	-15.19

Zealand Pharma A/S has higher revenue and earnings than its competitors. Zealand Pharma A/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Zealand Pharma A/S has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S’s competitors have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Zealand Pharma A/S and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	17.56%	16.17%
Zealand Pharma A/S Competitors	-12,357.18%	-197.96%	-30.56%

Summary

Zealand Pharma A/S beats its competitors on 7 of the 13 factors compared.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.